

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

Art Unit: 1612

Wagner, Jürgen et al.

Examiner: Webb, Walter E

INTERNATIONAL APPLICATION NO: PCT/EP2005/003663

FILED: April 07, 2005

U.S. APPLICATION NO: 10/599697

35 USC §371 DATE: October 05, 2006

FOR: Protein Kinase C Inhibitors for the Treatment of Autoimmune  
Diseases and of Transplant Rejection

MS: Amendment

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed:

☒ supplemental to the Information Disclosure Statement filed March 30, 2009.

If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to  
Deposit Account No. 19-0134 in the name of Novartis.

☒ This Information Disclosure Statement is being filed in accordance with 37 C.F.R.  
§1.97(c) or 37 C.F.R. §1.97(d).


☒ A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the  
references cited on the attached form(s) PTO-1449.

☒ Copies of the references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application  
and indicate that each reference was considered by returning a copy of the initialed PTO 1449  
form(s).

Respectfully submitted,



Leslie Fischer  
Attorney for Applicant  
Reg. No. 58,393

Novartis Pharmaceuticals Corporation  
One Health Plaza, Bldg. 101  
East Hanover, NJ 07936  
(862) 778-9308

Date: 12/11/10